LQDA ▾TradingViewOVTLYR consoleNews (1w)Earnings search — Liquidia Corporation

Healthcare · ETF XLV · as of 2026-09-22

Daily · EMA 10 / 20 / 50 · SMA 200 · VolPress: buy/sell split, 20-SMA, white dot = above avg · · E = earnings · RS vs SPY ⓘ · ● RS new high ⓘ
Liquidia Corporation NCM
Healthcare · Drug Manufacturers - Specialty & Generic

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Market cap
6.7B
P/E (TTM)
-
EPS (TTM)
-
Employees
216
IPO
2018-07-26
Website
liquidia.com

Price & today

$68.64 ATR(14) 3.19 (4.65%)
Stock today+3.33%
Sector ETF today+0.52%
Residual (stock-specific)+2.81%

Sector correlation

20-day correlation with XLV0.17
60-day correlation with XLV-0.02
Status normal

Decoupling fires when 60d corr − 20d corr > 0.20: stock used to track its sector but the relationship has weakened recently.

Technicals

10 EMA$67.68
20 EMA$69.12
50 EMA$71.48
EMA stackBEARISH
RSI(14)46.1
52-week high distance—
52-week low distance—

Signals

Market F&G44.9
Bull%13.8%
OVTLYR status SELL (34d)
Sector rank#33
Next earnings 2026-11-02 (TNS, 40d)
TradingView OVTLYR console More news (Google) Sector dashboard (XLV)

MarketSmith metrics - our compute

RS Rating
19.0
ADR%
3.9
RMV (tight)
9.0
Ext (ATR>20EMA)
-0.1
Rel Vol
80.0%
U/D 50d
0.84
U/D 25d
0.66
Accum/Dist 25d
0 / 1
EPS YoY
+251.0%
LoD dist
83.0
Off 52w High
26.7%
Above 52w Low
224.6%
1W / 1M
+4.4 / +0.0
Avg $Vol 50d
108.0M
Mkt Cap (B)
6.1
Trend 8/8
no
Sector XLV
+1.3% 1W
Base len (VCP)
10wk (6/4)
Coil (base shape)
85TVPX
not available: float_shares(NULL->no Float%)
What do these abbreviations mean?
RS Rating
- IBD-style relative strength vs SPY (weighted 3/6/9/12-mo). 70+ = leaders pool, 80+ = strong.
ADR%
- average daily range over 20 days. 4%+ = the fast movers the playbook prefers (selection order, not a gate).
RMV (tight)
- Relative Measured Volatility, 15 bars, scaled 0-100. <15 = tight coiled base (green), <35 moderate, high = loose/expanding - not a base right now.
Ext (ATR>20EMA)
- how many ATRs price sits above its 20-EMA. ≤1 = in value (green), >2 = extended/chasing (red) - prefer a pullback.
Rel Vol
- latest volume vs the 50-day average. 100% = normal; 140%+ = breakout confirmation.
U/D 50d / 25d
- up-day vs down-day volume over the window. 1.1+ = net accumulation (institutions buying); under 0.9 on the 25d = net selling.
Accum/Dist 25d
- heavy-volume up days vs heavy-volume down days in the last 25 sessions (close moved 0.2%+ on above-average volume). The institutional-participation footprint; 5+ distribution days = O'Neil caution line.
LoD dist
- close distance above the day low in % of ATR (100 = one full ATR off the low). High = strong close.
Off/Above 52w
- trend-template legs: within 25% of the 52-week high, at least 25% above the 52-week low.
Trend 8/8
- all 8 Minervini Trend Template criteria pass. Discovery floor, NOT an entry signal - entries come from the VCP pivot.
Base len (VCP)
- weeks since the VCP base started on the latest scan. 10wk+ bases carry the edge; short stacked bases test below random.

Fundamentals & valuation - reference, not entry inputs

P/E (TTM)
-
Fwd P/E
-
PEG
-
Price/Book
-
Profit margin
-
ROE
-
Debt/Equity
-
Rev growth
-
Analyst target
-
Analyst rating
-
Institutional %
-
Insider %
-
Float %
-
Valuation and analyst figures are Yahoo company stats (weekly refresh, ~3,000 larger names - blanks are honest gaps); logo, employees, website and IPO date are Massive company reference. Momentum/VCP entries do not use valuation - this card is context so you do not have to leave the page.

Company data - context read, not entry inputs

Industry rank
18 / 146
Industry
Drug Manufacturers - Specialty & Generic
Float
-
Float turnover 20d
-
Avg $Vol 20d / 50d
80.7M / 108.0M
Days to cover
-
Short % float
-
Institutional %
-
Weinstein stage
2
Float, short interest and institutional % come from Yahoo company stats, refreshed weekly for ~3,000 larger names - a blank means Yahoo does not publish the figure for this stock, not that it is zero. Dollar volume and float turnover are computed from our own price bars; industry rank from our rotation data; stage from the weekly chart.

Quarterly EPS - earnings acceleration

A dash in %Chg is deliberate: the year-ago figure was a loss, so a growth % would be meaningless. A dash in Sales means we have no revenue figure for that quarter - read it as a gap in our data, not as zero revenue.

QuarterEPS ($)%Chg YoYSales ($M)%Chg
Nov-24 -0.39 - 4.4 +21%
Mar-25 -0.45 - 2.9 -36%
May-25 -0.45 - 3.1 +5%
Aug-25 -0.49 - 8.8 +142%
Nov-25 -0.04 - 54.3 +1122%
Mar-26 0.15 - 92.0 +3055%
May-26 0.52 - 132.9 +4158%
Aug-26 0.74 - 171.7 +1843%
† = SEC carries this same fiscal quarter under a second period-end with a materially different figure (hover for it) - a restatement, merger recast or successor-period split; %Chg is blanked when the two are more than 15% apart. It fires only when the two period-ends DISAGREE, so it is a floor, not a guarantee that the rest of the column shares one basis · ‡ = the revenue concept changed from the previous quarter WITH A FIGURE (hover for both) - a blank row in between is skipped, as the eye does - a step at that row is a change of basis, not necessarily of business · EPS = Yahoo eps_actual (the figure MarketSmith/Deepvue show) - whether a given quarter is GAAP or excludes a one-off follows the filing, so it can sit either side of another vendor's number; AAPL's Oct-24 row, the Sep-2024 fiscal quarter, is $0.97 here - GAAP, including the EU tax charge - where TradingView's year implies $1.64 · Sales ($M) = SEC EDGAR quarterly revenue (fiscal Q4 derived as FY minus 9-mo) · quarter = report month · %Chg blank = prior-year base under $0.05 (not meaningful).

Recent news - our DB (Finnhub + OVTLYR)